Status:
RECRUITING
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
Lead Sponsor:
RemeGen Co., Ltd.
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small ...
Detailed Description
Primary objective: to evaluate the efficacy of RC148 injection as monotherapy or combination therapy in patients locally advanced or metastatic non-small cell lung cancer;
Eligibility Criteria
Inclusion
- Voluntarily participate in the study and signed the ICF;
- Be willing to and able to act on the trial and the follow up procedures;
- Male or female, aged 18-80 years;
- Expected survival ≥ 3 months;
- ECOG PS score 0 or 1;
- All participants to be enrolled in cohorts 1-5 must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced or metastatic NSCLC (stage IIIB//IIIC/IV according to the 8th edition of UICC/AJCC) and not amendable to curative surgery or radiation as assessed by investigator.
Exclusion
- Histopathologically or cytologically confirmed small cell lung cancer;
- Received major surgeries and still in recovery within 28 days before the first dose;
- Received any live vaccine within 28 days prior to the first dose or plan to be vaccinated during the study (except for COVID-19 vaccine);
- Received immune checkpoint inhibitor (anti-PD-1/PD-L1/CTLA-4 antibody) or other immune checkpoint inhibitor treatment within 28 days prior to the first dose, or experienced prior permanent immunotherapy discontinuation due to immunotoxicity;
- Participated in other clinical trials and received other investigational anti-tumor therapy within 28 days prior to the first dose;
- Poor compliance and unable to complete the study procedures as assessed by investigator;
- Have any other medical conditions, abnormal physical examinations or laboratory examinations that would be suspected interfere with participation or evaluation of the trial or increase the risk to the participant, in view of the investigator.
Key Trial Info
Start Date :
March 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06883630
Start Date
March 13 2025
End Date
July 31 2027
Last Update
July 15 2025
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tiantan Hospital of Capital Medical University
Beijing, Beijing Municipality, China
2
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
3
Shunde Hospital of Southern Medical University
Foshan, Guangdong, China
4
The First People's Hospital of Shunde
Foshan, Guangdong, China